Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, Oliver Bechter, S. Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset‐Séguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Kal Mohan, Ebony Coates, Vladimir Janković, Nathalie Fiaschi, Emmanuel Chiebuka Okoye, Ioannis D. Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury
Topics & Concepts
MedicineRegimenInternal medicineClinical endpointBasal cell carcinomaOncologyVismodegibClinical trialBasal cellHedgehog Signaling Pathway StudiesNonmelanoma Skin Cancer StudiesCutaneous Melanoma Detection and Management